Is Regeneron Pharmaceuticals (REGN) Still Attractive After Recent Share Price Strength?

robot
Abstract generation in progress

This article analyzes Regeneron Pharmaceuticals (REGN) at its current share price of US$766.02 using a 6-point valuation framework. It employs a Discounted Cash Flow (DCF) model and P/E ratio analysis, both suggesting the stock is undervalued. The article also presents “Bull” and “Bear” narratives with differing fair value estimates (US$873.78 and US$730.00 respectively) to help investors assess the company’s future prospects.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin